Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553558 | 1.00 | DNM1 (0.50) | DNM1OPRM1CA1CA2CA9 | |
| SCHEMBL28332607 | 0.96 | DNM1 (0.47) | DNM1OPRM1CA1CA2CA9 | |
| SCHEMBL27794236 | 0.91 | MEN1 (0.46) | DNM1SPHK1HTT | |
| SCHEMBL27772901 | 0.91 | MEN1 (0.46) | DNM1SPHK1HTT | |
| SCHEMBL29059868 | 0.89 | ALDH1A1 (0.49) | DNM1 | |
| SCHEMBL10726356 | 0.84 | DNM1 (0.52) | DNM1OPRM1CA1CA2CA9 | |
| SCHEMBL18567983 | 0.84 | DNM1 (0.52) | DNM1OPRM1CA1CA2CA9 | |
| SCHEMBL27795023 | 0.81 | DNM1 (0.48) | DNM1OPRM1SPHK1HTT | |
| SCHEMBL27578847 | 0.81 | DNM1 (0.48) | DNM1OPRM1SPHK1HTT | |
| SCHEMBL9273623 | 0.81 | DNM1 (0.48) | DNM1OPRM1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724419-A1 | A NANOPARTICLE COMPOSITION AND RELATED METHODS THEREOF | Agency for Science, Technology and Research (SG) | 2026-04-15 | — | — | EP | claimed |
| EP-4673116-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF | Agency for Science, Technology and Research (SG) | 2026-01-07 | — | — | EP | claimed |
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2025-10-09 | — | — | US | claimed |
| EP-4551199-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | PolyPlus Transfection (FR) | 2025-05-14 | — | — | EP | claimed |
| WO-2025090023-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND, AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-05-01 | — | — | WO | claimed |
| WO-2024253582-A1 | A NANOPARTICLE COMPOSITION AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-12-12 | — | — | WO | claimed |
| WO-2024205499-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-10-03 | — | — | WO | claimed |
| WO-2024181917-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-09-06 | — | — | WO | claimed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2024008967-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2024-01-11 | — | — | WO | claimed |
| US-20220378702-A1 | PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2022-12-01 | — | — | US | claimed |
| US-20220370624-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022235972-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | claimed |
| WO-2022235923-A2 | PEPTIDE-LIPID CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-12637691-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139236-A1 | REPROGRAMABLE TNPB POLYPEPTIDES AND USE THEREOF | THE BROAD INST INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102528-A1 | TUMOR ANTIGENS FOR LUNG CANCER AND USES THEREOF | Université de Montréal (CA) | 2026-05-21 | — | — | WO | disclosed |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005026372-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005007196-A2 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312287-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | NPC1L1, CETP, LNPK | DNM1 1449/4885OPRM1 3338/4885CA1 3870/4885 |
| US-20220370624-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | PHOSPHO1, LNPEP, SLC27A1 | DNM1 443/4885OPRM1 3880/4885CA1 2493/4885 |
| US-20260139236-A1 | REPROGRAMABLE TNPB POLYPEPTIDES AND USE THEREOF | RBM26, TRRAP, RNASEL | DNM1 3413/4885OPRM1 2940/4885CA1 4855/4885 |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | ABHD16A, LDLR, RNASE1 | DNM1 1717/4885OPRM1 4261/4885CA1 4745/4885 |
| US-12637691-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | JMJD7, ZMYND8, ZFR | DNM1 3704/4885OPRM1 3515/4885CA1 1165/4885 |
| US-20220378702-A1 | PEPTIDE-LIPID CONJUGATES | GLUL, ASNS, SLC7A11 | DNM1 1013/4885OPRM1 4331/4885CA1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.